Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 5, Issue 3, 2002, Pages 189-192

  Kote Jarai, Z ^a   Durocher, F ^b   Edwards, S M ^a   Hamoudi, R ^a   Jackson, R A ^a   Ardern Jones, A ^a   Murkin, A ^a   Dearnaley, D P ^a   Kirby, R ^c   Houlston, R ^a   Easton, D F ^b,c   Eeles, R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Association study; Genotyping; Glutathione peroxidase 1; Prostate cancer; Selenium

Indexed keywords

ALANINE; CYTOSINE; GLUTATHIONE PEROXIDASE; GUANINE; PEROXIDASE; POLYALANINE; SELENIUM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME ACTIVITY; EPIDEMIOLOGY; EXON; GENETIC CODE; GENOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE REPEAT; ONSET AGE; OXIDATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; ALLELES; GENES, P53; GENOTYPE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS; SELENIUM; TRINUCLEOTIDE REPEATS;

EID: 0036388339     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500569     Document Type: Article

References (14)

1. Eeles R, the UK Familial Prostate Study Co-ordinating Group and the CRC/BPG UK Familial Prostate Cancer Study Collaborators. Genetic predisposition to Prostate cancer. Prostate Cancer and Prostatic Disease 1999; 2: 9-15.
2. Clark LC et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998; 81: 730.
3. Yoshizawa K et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998; 90: 1219-1224.
4. Ghadirian P et al. A case-control study of toe-nail selenium and cancer of the breast, colon and prostate. Cancer Detec Prev 2000; 24: 305-313.
5. Nomura AM, Lee J, Stemmermann GN, Combs GF Jr. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 883-887.
6. Helzlsouer KJ et al. Association between alpha-tocopherol, gamma-tocopherol, selenium and susequent prostate cancer. J Natl Cancer Inst 2000; 20: 2018-2023.
7. Flohe L. Glutathione peroxidase. Basic Life Sci 1988; 49: 663-668.
8. Moscow JA et al. Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer. Carcinogenesis 1994; 15: 2769-2773.
9. Ratnasinghe D et al. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res 2000; 60: 6381-6383.
10. Easton D, Peto J, Babiker AG. Floating absolute-risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitary reference group. Stat Med 1991; 10: 1025-1035.
11. Aumann KD, Bedorf N, Brigelius-Flohe R, Schomburg D, Flohe L. Glutathione peroxidase revisited-simulation of the catalytic cycle by computer-assisted molecular modeling. Biomed Environ Sci 1997; 10: 136-155.
12. Tan M, Li S, Swaroop M, Guan K, Oberley LW, Sun Y. Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem 1999; 274: 12061-12066.
13. Chada S, Newburger P. Regulation of human glutathione peroxidase gene expression by selenium. Glutathione Centennial, Academic Press, 1989.
14. Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemol Biom Prev 2000; 9: 1171-1182.